AEHR · Aehr Test Systems

Current Thesis

Aehr Test Systems’ artificial-intelligence (AI) burn-in orders support a revenue-ramp thesis that requires the next results to preserve fiscal 2027 guidance and the shares to recover above Lake Street’s published $110 target before the $70.00 weekly-close invalidation fires. Burn-in screens semiconductor devices for early failures. The operating evidence remains the company’s 2026-07-14 guidance of $130–150 million in fiscal 2027 revenue, compared with $50.0 million reported for fiscal 2026, and its 2026-08-12 follow-on AI-processor order of $22 million. Company financial releases and order announcements.

Measured changes since the 2026-09-03 note are a higher reference close and additional analyst coverage. The adjusted daily series records $94.69 on 2026-09-11, exceeding both the 2026-09-02 close of $80.24 and the prior note’s $80.81 recovery test. Oppenheimer’s Edward Yang initiated coverage on 2026-09-10 with an Outperform rating and a $120 target. That replaces the previous description of an unchanged analyst sheet. Benzinga analyst actions.

As an inference, the narrative is maturing — Oppenheimer’s 2026-09-10 initiation extends coverage after Jefferies’ 2026-08-14 initiation, while the latest order announcement displayed in the company newsroom remains dated 2026-08-12. The earlier saturated assessment is less persuasive after renewed coverage and the 2026-09-11 recovery, but those observations cannot establish expanding investor participation. A new production customer and a weekly close above Lake Street’s $110 target would challenge that assessment; a weekly close below $70.00 would invalidate the recovery case. Ratings history and company newsroom.

Bullish and bearish views on Aehr Test Systems

The model's bull view on Aehr Test Systems (AEHR), in brief: Orders support the revenue ramp. The 2026-07-14 fiscal-year results reported quarterly bookings of $60.7 million and effective backlog of $100.6 million alongside fiscal 2027 revenue guidance of $130–150 million. Those are operating commitments and management guidance… The bear view: The conference test went unmet. Aehr’s 2026-09-03 release confirmed the scheduled 2026-09-10 Lake Street appearance, correcting the previous note’s uncertainty about participation. The newsroom reviewed on 2026-09-13 displays no subsequent customer announcement, so the previous… Both cases follow in full.

Bull Case

• Orders support the revenue ramp. The 2026-07-14 fiscal-year results reported quarterly bookings of $60.7 million and effective backlog of $100.6 million alongside fiscal 2027 revenue guidance of $130–150 million. Those are operating commitments and management guidance, respectively; they do not establish the timing of revenue recognition. Source: company fiscal-fourth-quarter release dated 2026-07-14.
• The lead customer ordered again. Aehr announced a $22 million follow-on wafer-level AI-processor order on 2026-08-12. The order supports repeat demand from an existing customer; it does not establish a second distinct customer. Company order announcement listing.
• Coverage expanded during the recovery. Oppenheimer initiated with a $120 target on 2026-09-10, following Jefferies’ $175 target dated 2026-08-14. These are third-party valuation opinions, not company revenue commitments. Dated analyst actions.

Bear Case

• The conference test went unmet. Aehr’s 2026-09-03 release confirmed the scheduled 2026-09-10 Lake Street appearance, correcting the previous note’s uncertainty about participation. The newsroom reviewed on 2026-09-13 displays no subsequent customer announcement, so the previous conference-specific customer-confirmation test was not met in that public record. Company newsroom.
• The revenue transition remains unreported. Fiscal 2026 revenue was $50.0 million in the 2026-07-14 results; the $130–150 million fiscal 2027 figure was guidance. No fiscal 2027 first-quarter results appear in the financial-release archive reviewed on 2026-09-13. Company financial releases.
• The drawdown remains substantial. The adjusted price series dated 2026-09-11 reports a 35.0% distance below the $145.61 trailing-year high and a three-month price decline of 12.7%. The higher September close has not erased that measured deterioration.

Setup & Price Structure

The public reference close is $94.69 on 2026-09-11. The same adjusted series reports a 14-period relative strength index (RSI) of 43.6, compared with 27.3 in the 2026-09-02 observation. These readings establish improved endpoint momentum; the limited observations supplied do not establish a durable base or identify the source of demand.

The 2026-09-11 close satisfies the earlier note’s requirement to exceed the 2026-08-28 close of $80.81 within its following two-week window. The $70.00 weekly-close boundary remains the research invalidation published on 2026-09-03; it is not presented as newly measured support. The recovery case is defined here as a weekly close above Lake Street’s $110 target while the next results preserve the fiscal 2027 revenue range, before that downside boundary is breached. Lake Street’s target remains dated 2026-07-15 in the ratings history updated 2026-09-10. Ratings history.

The observable attention evidence is the Jefferies and Oppenheimer initiation sequence dated 2026-08-14 and 2026-09-10. That sequence establishes additional research coverage, not crowded ownership or short covering. Current moving-average slopes and an updated short-interest observation are missing from this record, so neither is used to explain the recovery.

Catalyst Calendar (next 30 days)

• ~2026-10-01, estimated results date. ChartMill lists this date for Aehr’s next earnings report. It remains an external calendar indication: the company financial-release archive reviewed on 2026-09-13 contains no corresponding results-date announcement. The report would test whether the 2026-07-14 fiscal 2027 guidance survives the first reported quarter of the ramp. ChartMill calendar and company financial releases.
• ~2026-10-05, alternative estimated date. MarketBeat estimates this date for the same fiscal 2027 first-quarter report using historical reporting schedules. This is a conflicting estimate for one event, not an additional catalyst. The uncertainty concerns scheduling; a vendor date passing without results would not itself invalidate the operating thesis. MarketBeat earnings calendar.

What Would Change Our Mind

Loss of the July-range boundary retained in the 2026-09-03 research would end the recovery case: a weekly close below $70.00 is the gradeable condition. Withdrawal or reduction of the $130–150 million fiscal 2027 revenue guidance issued on 2026-07-14 would separately invalidate the operating premise. A quarterly revenue consensus is missing from the reviewed evidence, so no numerical quarterly miss threshold is asserted.

The positive resolution requires both a weekly close above Lake Street’s $110 target and preservation of the fiscal 2027 revenue range at the next results. A production order explicitly identifying an additional distinct AI customer would strengthen the evidence beyond the repeat-customer order announced on 2026-08-12. A conference appearance or another analyst initiation alone would not satisfy that customer test.

Correlation Notes

This remains a single-name setup: the evidence contains no synchronized peer-return series that supports a measured group correlation. Aehr’s 2026-08-04 silicon-photonics order and its more than $8 million of silicon-carbide orders announced on 2026-07-14 identify different demand channels alongside AI processors, but they do not establish independent share-price behavior. Source: company order releases dated 2026-08-04 and 2026-07-14.

The 2026-09-11 price recovery cannot be attributed to a semiconductor-group move from the observations available. The sample is too small to support a correlation claim.